A novel inhibitor of zipper-interacting protein kinase (ZIPK) was used to examine the involvement of ZIPK in the regulation of smooth muscle contraction. Pretreatment of de-endothelialized rat caudal arterial smooth muscle strips with the pyrazolo [3,4-
Introduction
The coordinated regulation of tone via protein kinases is a key functional property of vascular smooth muscle (VSM), and it is not surprising that a variety of signal transduction mechanisms can regulate VSM tone (Hirano, 2007; Kim et al., 2008; Wynne et al., 2009) . Of central importance to VSM tone generation is the relationship between cytosolic Ca 21 concentrations ([Ca 21 ] i ) and force generation. Greater force can be obtained in the absence of a change in [Ca 21 ] i through a Ca 21 sensitization process. Since blood flow is proportional to the fourth power of the vessel radius (Sutera and Skalak, 1993) , fine control of VSM tone is essential for maintenance of normal cardiovascular function. This is achieved primarily via signaling pathways that lead to Ca 21 sensitization of the contractile response. Furthermore, alterations in the sensitivity of VSM cells to [Ca 21 ] i have been hypothesized to underlie many cardiovascular diseases. For example, increased VSM contractility contributes to the severe arterial narrowing observed in vasospasm, chronic hypertension, and the decreased dilatory responses of arteries in obesity, diabetes, and aging (Katsumata et al., 1997; Uehata et al., 1997; Masumoto et al., 2002; Georgescu et al., 2011; Takeya et al., 2014) .
The biochemical systems that govern Ca 21 sensitization in VSM are complex and multifactorial; however, zipperinteracting protein kinase (ZIPK) has emerged as one of the most important. ZIPK has been linked to the regulation of diverse cellular processes, including cell motility, smooth muscle contraction, and programmed cell death (reviewed in Haystead, 2005; Shiloh et al., 2014; Usui et al., 2014) . ZIPK possesses an N-terminal kinase domain, central autoinhibitory region, nuclear localization sequence, and C-terminal leucine zipper (LZ) motif. ZIPK is a member of a larger family of protein kinases known as the death-associated protein kinases (DAPKs), and is also known as DAPK3. The kinase domain is most closely related to other DAPK proteins but also shares significant sequence and structural conservation with calmodulin-dependent kinase family members such as myosin light chain kinase (MLCK) Moffat et al., 2011; Shiloh et al., 2014) . In contrast to MLCK and the other DAPKs, ZIPK does not have a calmodulin-binding domain, and its activity is regulated independently of Ca 21 . ZIPK appears to be a key regulator of VSM contractility, and the kinase is implicated in diphosphorylation of the myosin 20-kDa regulatory light chain (LC 20 ) subunits of myosin II at Ser19 and Thr18 (Murata-Hori et al., 1999; Niiro and Ikebe, 2001; Borman et al., 2002; Moffat et al., 2011; Carlson et al., 2013) ; phosphorylation of the myosin phosphatase-targeting subunit 1 (MYPT1) of myosin light chain phosphatase (MLCP) at the inhibitory sites, Thr697 and Thr855 (Endo et al., 2004; MacDonald et al., 2001a) ; and phosphorylation of the protein kinase C (PKC)-potentiated inhibitory protein for myosin phosphatase of 17 kDa (CPI-17) at Thr38 (MacDonald et al., 2001b) . Ultimately, these targets are thought to be the primary mediators of ZIPK effects on VSM contraction; however, several novel ZIPK regulators have been revealed in recent years. Notably, the prostate apoptosis response-4 (Par-4) protein is suggested to facilitate VSM contraction by acting as a cytoskeletal scaffold for ZIPK (Vetterkind and Morgan, 2009; Vetterkind et al., 2010) . While the upstream activating pathways for ZIPK have yet to be resolved, evidence suggests that the kinase can be activated in VSM in response to external stimuli (MacDonald et al., 2001a; Graves et al., 2005; Hagerty et al., 2007) , and ZIPK can be phosphorylated by Rho-associated coiled coil-containing protein kinase (ROCK) (Hagerty et al., 2007) .
Pharmacological agents can provide powerful insight into signaling mechanisms if used appropriately. Four independent groups have recently reported the development of novel ZIPK inhibitory compounds: 1) Velentza et al. (2003) reported the first small molecule DAPK inhibitor, an alkylated 3-amino-6-phenylpyridazine; 2) Okamoto et al. (2009 Okamoto et al. ( , 2010 used structure-based, virtual screening to identify DAPK1 and ZIPK inhibitors with a 2-phenyl-4-(3-pyridinylmethylene)-5(4H)-oxazolone core; 3) Huber et al. (2012) identified inhibitory oxo-b-carboline compounds that do not rely on canonical ATP competition; and 4) Carlson et al. (2013) used a chemoproteomic fluorescence linked enzyme chemoproteomic strategy screening to identify an aryl-thiopyrazolo [3,4-d] pyrimidinone-i.e., 2-((1-(3-chlorophenyl)-4-oxo-4,5-dihydro-1H-pyrazolo [3,4-d]-pyrimidin-6-yl)thio)propanamide (HS38)-that competitively inhibits ZIPK. HS38 displays similar or greater potency for ZIPK and has fewer off-target liabilities than other published ZIPK inhibitors (Carlson et al., 2013) . The availability of a cell-permeable, potent, and selective inhibitor provides a novel opportunity to examine aspects of ZIPK signaling in VSM that were previously not attainable, and we have used HS38 to study the mechanistic role of ZIPK in Ca 21 sensitization of VSM.
Materials and Methods
Materials. HS38 and 1-(3-chlorophenyl)-6-((2-hydroxyethyl)thio)-1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one (HS43) were synthesized in the Haystead Laboratory at Duke University as previously described (Carlson et al., 2013) . Only trace impurities were identified (,1% by liquid chromatography coupled to mass spectrometry). Calyculin A (CLa), angiotensin II (AngII), endothelin-1 (ET-1), and U46619 were purchased from EMD Millipore (Billerica, MA) and phenylephrine (PE) was obtained from Sigma Chemical Co. (St. Louis, MO). The Supersignal West Femto Chemiluminescence Kit was purchased from GE Healthcare (Piscataway, NJ). Antibodies specific for CPI-17 and Par-4 were purchased from EMD Millipore. Phosphospecific antibodies for MYPT1 phosphorylated at Thr697 or Thr855 were purchased from EMD Millipore. Phos-Tag-acrylamide was purchased from NARD Chemicals, Inc. (Kobe City, Japan). Purified ROCK2 was purchased from SignalChem (Richmond, British Columbia, Canada). LC 20 (Hathaway and Haeberle, 1983) and MLCK (Ngai et al., 1984) proteins were purified from chicken gizzard as previously described. All other chemicals were reagent grade and were obtained from Sigma Chemical Co. or VWR (Mississauga, Ontario, Canada) .
In Vitro Kinase Assays. ROCK2 and MLCK activities were assayed at 25°C with LC 20 protein substrate under standard conditions (25 mM HEPES, pH 7.4, 1 mM MgCl 2 , 0.2 mM ATP, and 2 mCi of [g-32 P]-ATP). Reactions were initiated by the addition of ATP and terminated by spotting the mixture onto phosphocellulose P81 paper. After extensive washing with 20 mM H 3 PO 4 , 32 P incorporation was determined by scintillation counting.
Tissue Preparation and Force Measurements. Caudal arteries were removed from male Sprague-Dawley rats (∼300 g) that had been anesthetized and euthanized according to protocols approved by the University of Calgary Animal Care and Use Committee. The arteries were cleaned of excess adventitia, denuded of endothelium, and cut into helical strips (1.5 mm Â 6 mm). Muscle strips were mounted on a Grass isometric force transducer (FT03C) and force was recorded as previously described (Moffat et al., 2011) . Intact tissues were treated with CLa (0.5 mM) in HEPES-buffered Tyrode's solution containing 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , 5.6 mM glucose, and 10 mM HEPES, pH 7.4. Isolated smooth muscle strips, preincubated with HS38 or vehicle (dimethylsulfoxide), were also stimulated with the following contractile agonists in HEPES-buffered Tyrode's solution: the thromboxane A 2 mimetic U46619, ET-1, AngII, PE, or KCl (87 mM KCl replaced 87 mM NaCl in HEPES-buffered Tyrode's solution). At selected times, muscle strips were flash frozen in 10% (w/v) trichloroacetic acid, 10 mM dithiothreitol in acetone, followed by 3 Â 10 second washes in 10 mM dithiothreitol in acetone. Tissues were then lyophilized overnight prior to protein extraction.
Analysis of LC 20 , MYPT1, Par-4, and CPI-17 Phosphorylation. Protein was extracted from each lyophilized tissue in 1 ml of SDS-gel sample buffer with constant shaking for 16 hours at 4°C. Tissue proteins were resolved by Phos-Tag SDS-PAGE and western blotting for the measurement of LC 20 , Par-4 and CPI-17 phosphorylation (Takeya et al., 2008; Moffat et al., 2011; Ihara et al., 2015) , and by SDS-PAGE and western blotting with phosphospecific antibodies for MYPT1 phosphorylation (Grassie et al., 2012; Mills et al., 2015) . For CPI-17, 12.5% acrylamide and 30 mM Phos-Tag reagent were used, and proteins were transferred to polyvinylidene difluoride (Roche Life Science, Quebec, Canada) overnight at 25 V and 4°C in 10 mM CAPS, pH 11, 10% methanol. For LC 20 , 12.5% acrylamide and 50 mM Phos-Tag reagent were used, and proteins were transferred to polyvinylidene difluoride overnight at 27 V and 4°C in 25 mM TrisHCl, pH 7.5, 192 mM glycine, 10% (v/v) methanol. Following transfer, proteins were fixed on the membrane by incubation for 20 minutes with 0.5% glutaraldehyde in phosphate-buffered saline and nonspecific binding sites were blocked with 5% (w/v) nonfat dry milk (for LC 20 ) or with 2% enhanced chemiluminescence blocking reagent (for CPI-17) in Tris-buffered saline/Tween 20 for 1 hour at room temperature. Membranes were incubated overnight with anti-LC 20 (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:500 dilution in 1% (w/v) nonfat dry milk. Membranes were then incubated for 1 hour with 
ZIPK and Vascular Smooth Muscle Contraction
horseradish peroxidase-conjugated secondary antibody (Chemicon, Temecula, CA) at 1:10,000 dilution or for 2 hours with anti-CPI-17 (EMD Millipore) at 1:5000 dilution, and then for 1 hour with biotinlabeled secondary antibody (EMD Millipore) at 1:10,000 dilution, followed by streptavidin-horseradish peroxidase (Pierce Chemical Co., Rockford, IL) at 1:5000 dilution for 30 minutes. For Par-4, 7.5% acrylamide and 60 mM Phos-Tag reagent were used, proteins were transferred to 0.2-mm nitrocellulose membrane overnight at 28 V and 4°C in 25 mM Tris-HCl, pH 7.5, 192 mM glycine, 10% (v/v) methanol, blocked with 5% skim milk in Tris-buffered saline/Tween 20 for 1 hour at room temperature, and incubated with anti-Par-4 (Abcam, Toronto, Ontario, Canada) at 1:5000 dilution for 2 hours at room temperature, followed by anti-rabbit IgG (EMD Millipore) at 1:5000 dilution for 1 hour at room temperature. For analysis of MYPT1 phosphorylation, tissue homogenates were resolved by 10% SDS-PAGE and transferred to nitrocellulose membranes. Membranes were incubated with anti-[phospho-Thr697]-MYPT1 (EMD Millipore) at 1:3500 dilution or anti-[phospho-Thr855]-MYPT1 (EMD Millipore) at 1:3000 dilution, and then for 1 hour with horseradish peroxidase-conjugated secondary antibody (EMD Millipore; 1:5000 dilution). Smooth muscle a-actin was used as a loading control with antibodies from Cytoskeleton Inc. (Denver, CO; 1:5000 dilution). All western blots were visualized with West Femto enhanced chemiluminescence reagent using a LAS4000 Imaging Station (GE Healthcare), ensuring that the representative signal occurred in the linear range. Quantification was performed by densitometry with ImageQuant TL software (GE Healthcare). LC 20 phosphorylation stoichiometry was calculated as follows: mol
Data Analysis. Values are presented as the mean 6 S.E.M., with n indicating the number of animals (tissue experiments). Data were analyzed by Student's t test (two-tailed). For comparison of multiple groups, significance was determined by two-way analysis of variance with Dunnett's post hoc test. Differences were considered to be statistically significant when P , 0.05.
Results
The pyrazolo [3,4-d] pyrimidinone derivative HS38 was previously characterized as a potent inhibitor of ZIPK (Carlson et al., 2013) . HS38 acts as a competitive inhibitor with respect to ATP and was reported to be most potent toward ZIPK (K d 5 280 nM), DAPK1 (K d 5 300 nM), and proviral integrations of Moloney virus 3 (PIM3) (K d 5 810 nM), 10-fold less potent against IRAK4 and PIM1, 100-fold less potent against PIM2 and MLCK, and inactive against ROCK2. Indeed, more detailed in vitro kinetic assessments of the inhibitory potential of HS38 toward ROCK2 and MLCK indicated that it has no significant effect on these contractile kinases at concentrations up to 100 mM (Fig. 1, A and B) . We employed isolated rat caudal arterial smooth muscle strips as a model VSM tissue and assessed the concentration and time dependence of HS38 effects on contractile responses. Muscle strips were incubated in Ca 21 -containing HEPES buffer with HS38 or vehicle prior to addition of the type 1 and 2A phosphatase inhibitor CLa, which by inhibiting endogenous MLCP activity unmasks basal Ca 21 -independent LC 20 kinase activities to induce a slow, sustained contraction (Wilson et al., 2005b; Sutherland and a Denotes CLa (0.5 mM) alone. b Denotes CLa + HS38 (50 mM). Fig. 2 . Reversibility of the inhibitory effect of HS38 on CLa-induced contraction. De-endothelialized rat caudal arterial smooth muscle strips in HEPES-buffered Tyrode's solution were preincubated for 30 minutes (A) or 3 hours (B) with vehicle (dimethylsulfoxide) or HS38 (100 mM). HS38 was retained or washed out for 30 minutes prior to addition of CLa (0.5 mM) for 3 hours to elicit a sustained contractile response. The time required to reach half-maximal force (t 1/2 ) was calculated and normalized to the vehicle control, which had never seen HS38. Values indicate the mean 6 S.E.M. (n = 3) with the control value set at 100%. *, Significantly different from the force evoked in the absence of HS38 (vehicle control); #, significantly different from the force evoked in the presence of HS38; nsd, no significant difference from vehicle control. Statistical significance assessed by analysis of variance with Dunnett's post hoc test, P , 0.05. . HS38 appeared to attenuate the velocity of the contractile responses, whereas the steady-state level of force induced by CLa was unaffected by ZIPK inhibition (Fig. 1, C and D), a result that was previously demonstrated (Carlson et al., 2013) . As shown in Table 1 , the mean steady-state force induced by CLa was ∼160% of that induced by KCl (87 mM) and was unaffected by pretreatment with HS38. We did observe variability in the steady-state force levels induced by CLa relative to KCl from tissue to tissue, as indicated by the S.D. values in parentheses in Table 1 . This variability can be attributed to variations in the dimensions of the muscle strips. The latency period, i.e., the time from addition of CLa to the onset of contraction, and the half-time from the initiation of contraction to the plateau of the contractile response, in addition to the t 1/2 values (the half-time from addition of CLa to the plateau of the contractile response) were all significantly increased in the presence of HS38 (Table 1 ). Significant increases in t 1/2 were observed at HS38 concentrations $10 mM, and maximal effects (∼2-fold increase in t 1/2 ) were observed at HS38 concentrations $50 mM (Fig. 1E) . On the other hand, increasing HS38 concentration did not affect the maximal developed force (Fig. 1F) . We addressed the possibility that HS38 may influence [Ca 21 ] i by examining Fluo-4-loaded, de-endothelialized rat caudal artery strips. As shown in Supplemental Fig. 1 , HS38 had no effect on the depolarization-induced Ca 21 transient. Finally, the effects of HS38 on the contractile response to CLa were found to be reversible. Treatment of de-endothelialized rat caudal arterial smooth muscle strips with HS38 (50 mM for 30 minutes or 3 hour), followed by washout, restored t 1/2 values of CLa-induced contraction to that observed with no prior exposure to HS38 (Fig. 2, A and B) .
The effect of HS38 on LC 20 phosphorylation was assessed to determine if inhibition of LC 20 phosphorylation underlies the HS38-induced reduction of the rate of CLa-induced contraction. HS38 suppressed CLa-induced LC 20 phosphorylation in a concentration-dependent manner, with significant inhibition observed at HS38 concentrations $25 mM (Fig. 3A) . The inhibitory effect of HS38 on LC 20 phosphorylation was confirmed by analysis of the time course of CLa-induced phosphorylation of LC 20 in the absence and presence of HS38 (100 mM) (Fig. 3, B-D) . The fact that LC 20 phosphorylation was not abolished by HS38 is consistent with the unmasking of the activities of other kinases, such as integrin-linked kinase (Wilson et al., 2005b) , upon CLa treatment.
ZIPK was originally isolated from smooth muscle as a MLCP-associated kinase (MacDonald et al., 2001a) , and studies have demonstrated its ability to phosphorylate MYPT1 (the regulatory, myosin-targeting subunit of the phosphatase) in vitro and in situ (MacDonald et al., 2001a; Endo et al., 2004; Moffat et al., 2011) . A basal level of phosphorylation was observed at both Thr inhibitory sites, Thr697 (Fig. 4A) and Thr855 (Fig. 4D) . Exposure of smooth muscle strips to HS38 reduced the basal phosphorylation observed under resting conditions (time zero) at both sites (Fig. 4 , B and E), thus there is likely some basal ZIPK activity (or other kinase activity influenced by ZIPK) that contributes to MYPT1 phosphorylation under rest/basal conditions. It is noticeable that the electrophoretic mobility of phospho-MYPT1-immunoreactive bands decreased with time of exposure to CLa, suggesting that MYPT1 is hyperphosphorylated at multiple sites upon phosphatase inhibition. After normalizing the MYPT1 phosphorylation immunosignals against a-actin to account for loading variability, we were also able to report the change in phosphorylation signal relative to the initial basal/resting level. The application of HS38 resulted in an unexpected accumulation of MYPT1 phosphorylation at both Thr697 (Fig. 4C) and Thr855 (Fig. 4F ) when compared with CLa stimulation alone. We have previously observed increased MYPT1 phosphorylation upon blockade of ZIPK signaling in rat caudal artery (Moffat et al., 2011) ; this observation was made during loading of recombinant, kinase-dead ZIPK protein into Triton-skinned muscle strips Fig. 4 . The effect of HS38 on CLa-induced phosphorylation of MYPT1 at Thr697 and Thr855. The time courses of MYPT1 phosphorylation at Thr697 (A-C) and Thr855 (D-E) were analyzed by SDS-PAGE and western blotting with phosphospecific antibodies following stimulation of caudal arterial smooth muscle strips with CLa (0.5 mM) in the presence of vehicle (dimethylsulfoxide) (A and D) or HS38 (100 mM) (B and E). Cumulative quantitative data showing the time course of MYPT1 phosphorylation (fold increase relative to levels at time zero) for Thr697 (C) and Thr855 (F) in the absence and presence of HS38 (100 mM) are provided. a-Actin was used as the loading control. Data are representative of four independent experiments. *, Statistical significance assessed with the Student's t test (two-tailed), P , 0.05.
with MLCP inhibition by microcystin-LR. We have interpreted this phenomenon to be a result of coincident unmasking of kinase activities with MLCP inhibitors and suppression of ZIPK activity. The resulting changes associated with the contractile architecture may allow the phosphorylation sites of MYPT1 to become more accessible, as theorized by Vetterkind et al. (2010) and Vetterkind and Morgan (2009) .
The in vitro phosphorylation of CPI-17 by ZIPK has been reported previously (MacDonald et al., 2001b) . Treatment of caudal arterial smooth muscle strips with CLa resulted in slow stoichiometric phosphorylation of CPI-17 at several sites, as shown by Phos-Tag SDS-PAGE (Fig. 5A) . In this case, HS38 had no effect on CLa-induced CPI-17 phosphorylation stoichiometry (Fig. 5B) .
The Par-4 (36 kDa) protein is expressed in differentiated VSM cells (Vetterkind and Morgan, 2009; Vetterkind et al., 2010) and is suggested to facilitate contraction by acting as a cytoskeletal scaffold for ZIPK. Therefore, we investigated the effects of HS38 on Par-4 phosphorylation in response to CLa stimulation of caudal arterial smooth muscle and observed that CLa treatment induced the phosphorylation of Par-4 at multiple sites (Fig. 6A) . Eight distinct phosphorylated species were detected by Phos-Tag SDS-PAGE; however, HS38 (100 mM) had no effect on the rate or maximal stoichiometry of Par-4 phosphorylation (Fig. 6, A-C) . Although HS38 has been described as a potent and selective ZIPK inhibitor, it does retain some off-target activity toward members of the PIM kinase family (Carlson et al., 2013) , which have roles in cell growth, proliferation, apoptosis, and regulation of signal transduction cascades (Alvarado et al., 2012) . Currently, there are no reports of PIM kinases contributing to smooth muscle contractility; however, we felt it prudent to assess whether any of the observed effects of HS38 on VSM contractility could be attributed to inhibition of PIM kinases. In this regard, a structural ortholog (HS43) was developed from the HS38 backbone (Carlson et al., 2013) . This compound retains selective potency toward PIM3 with minimal activity toward ZIPK. The HS43 compound was applied to de-endothelialized rat caudal arterial strips, and the contractile responses to CLa were monitored (Fig. 7A) . No effect was observed for HS43 on the velocity of contraction (Fig. 7B ) or maximal force (Fig. 7C) . Finally, CLa-induced phosphorylations of LC 20 (Fig. 7D) , E and F), and MYPT1 (Fig. 7, G and H) were also unaffected by inhibition of PIM3 kinase activity with HS43. The development of a potent and selective ZIPK inhibitor provides the opportunity to examine upstream receptorsignaling modules that are linked to ZIPK-dependent contractile responses. Isolated rat caudal arterial smooth muscle strips were again employed since receptor-mediated contractile responses have been extensively explored in this VSM tissue ( Weber et al., 1999; Mita et al., 2002; Wilson et al., 2005a,b; Grassie et al., 2012) . The typical contractile response of this tissue to agonist stimulation can be divided into an initial, rapid phasic response and a sustained, steady-state tonic response. The effects of HS38 pretreatment on the contractile responses to a range of agonists were investigated (Fig. 8A) . PE (1 mM), ET-1 (0.1 mM), and high-[K 1 ] extracellular solution (87 mM KCl) induced robust contractile responses; other stimuli [the thromboxane A 2 mimetic U46619
(1 mM) and AngII (0.1 mM)] elicited contractile responses of reduced magnitude. Both the force developed in the early phasic response (i.e., peak tension at 2-5 minutes) and the sustained tonic response (i.e., sustained force at 15 minutes) to all agonists were significantly inhibited by pretreatment with HS38 (Fig. 8, B and C) .
Agonist-induced contractions were associated with LC 20 phosphorylation exclusively at a single site (Fig. 9A) , previously identified as Ser19, as expected (e.g., Sutherland and Walsh, 2012) . LC 20 phosphorylation was significantly increased at the peak of the contractile response to PE, U46619, KCl, and ET-1 (Fig. 9, A and B) . All of these agonist-induced increases in LC 20 phosphorylation were abolished or significantly reduced by preincubation of the tissue with HS38 (Fig. 9, A and B) . In addition, the data showed no change in LC 20 phosphorylation Fig. 7 . The effect of PIM kinase inhibitor HS43 on CLa-induced contraction and phosphorylation of LC 20 , Par-4, and MYPT1. (A) De-endothelialized rat caudal arterial smooth muscle strips were treated with CLa (0.5 mM) in the presence of vehicle [dimethylsulfoxide], HS38 (100 mM), or HS43 (100 mM). The force was recorded continuously for the calculation of t 1/2 (time required to reach half-maximal force) (B) and maximal force (C). LC 20 (D) and Par-4 phosphorylations (E and F) were quantified by Phos-Tag SDS-PAGE and western blotting of tissues harvested at maximal force. MYPT1 phosphorylation at Thr697 and Thr855 was analyzed by western blotting with phosphospecific antibodies (G and H). Values in (B-D), (F), and (H) indicate the mean 6 S.E.M. (n = 3). *, Significantly different from the t 1/2 value found with vehicle; #, significantly different from the t 1/2 value evoked with HS38. Statistical significance was assessed by analysis of variance with Dunnett's post hoc test, P , 0.05.
following stimulation with AngII; however, a significant decrease was observed during AngII treatment in the presence of HS38. The effect of HS38 on agonist-induced phosphorylation of MYPT1 at Thr697 and Thr855 was also investigated. PEinduced Thr697 phosphorylation was reduced by ∼50% by HS38. Thr855 phosphorylation induced by PE, KCl and ET-1 was also suppressed by ∼50% by HS38 (Fig. 9, C and D) . Finally, agonist-induced phosphorylation of CPI-17 was assessed in the absence or presence of HS38 (Fig. 9, E and F) . Stimulation with all agonists (i.e., PE, U46619, KCl, AngII, and ET-1) enhanced CPI-17 phosphorylation relative to control, and HS38 pretreatment significantly suppressed the increase in CPI-17 phosphorylation induced by PE, AngII, and ET-1. In contrast, HS38 treatment had no influence on CPI-17 phosphorylation induced with U46619 or KCl.
Discussion
The inhibitory potential of the HS38 molecule against ZIPK was first defined in 2013, and some basic assessments of its effects on smooth muscle cells and tissues were completed to support its potential utility as a lead scaffold for future development and application to cardiovascular systems (Carlson et al., 2013) . In this regard, HS38 could alter ex vivo contractile force ] extracellular solution (87 mM KCl); iv, thromboxane A 2 mimetic (U46619, 1 mM); v, AngII (0.1 mM); and vi, CLa (0.5 mM). The force generated relative to the peak of the initial contraction induced by KCl was calculated from the individual contraction profiles. Tissues were quick frozen upon reaching peak force in the initial phasic contraction (.) or upon reaching the sustained tonic contraction maintained at the end of the trace (,). Values (mean 6 S.E.M., n = 3) are provided for the contractile force measured for the phasic (B) and tonic (C) components. *, Significantly different from the force evoked in the absence of HS38 (Student's t test, two-tailed, P , 0.05); DMSO, dimethylsulfoxide. development of various smooth muscles isolated from rabbit, rat, and mouse. HS38 could attenuate LC 20 phosphorylation in human coronary and aorta VSM cells in response to stimulation with serum and sphingosine-1-phosphate, respectively. In addition, HS38 suppressed Ca 21 -independent force production and LC 20 phosphorylation in permeabilized rabbit ileum treated with the MLCP inhibitor microcystin-LR. The lag time to the onset of force was increased, and the rate of force development was decreased. Additional pilot studies with rat caudal artery revealed the ability of HS38 to attenuate LC 20 phosphorylation and contractile force development. The initial findings supported a novel hypothesis that the ability of ZIPK to regulate the Ca 21 sensitization of smooth muscle contraction is conserved across species and smooth muscle tissues. Collectively, these results provided conclusive support for the role of ZIPK in the Ca 21 -independent phosphorylation of LC 20 ; however, the role of the kinase in agonist-dependent contraction remained largely unexamined. Herein, we were able to employ HS38 to comprehensively define the mechanistic role for ZIPK in the Ca 21 -sensitizing pathways that regulate VSM contractile tone.
Intriguing differences were observed for the ZIPKdependent contractile responses of caudal arterial strips, depending on the mode of activation. Treatment with CLa to inhibit type 1 and 2A phosphatases (including MLCP, a type 1 phosphatase), and thereby unmask endogenous kinase activities, yielded robust LC 20 mono-and diphosphorylation that was sensitive to ZIPK inhibition by HS38; however, the suppression of ZIPK activity did not relieve MLCP inhibition, i.e., significant amounts of CLa-induced MYPT1 phosphorylation at Thr697 and Thr855 were still observed in the presence of HS38. In contrast, agonist-induced stimulation of G protein-coupled receptor (GPCRs) and activation of downstream Ca 21 sensitization pathways elicited notable effects on phosphorylation of MYPT1 and CPI-17, as well as LC 20 . Based on these distinct responses, we speculate that two functional pools of ZIPK exist in this VSM tissue: 1) a constitutively active ZIPK associated with the myosin II compartment, and 2) an inactive ZIPK pool that is intimately associated with MLCP and its regulatory apparatus (e.g., Par-4, CPI-17, and the myosin phosphatase-Rho interacting protein, M-RIP). The first pool of ZIPK would be available to Various reports in the literature have described distinct forms of ZIPK in VSM. Independent methods have been used to separately purify ZIPK as a MLCP-associated kinase (MacDonald et al., 2001a ) and a Ca 21 -independent LC 20 kinase (Borman et al., 2002) , both of which were 32 kDa proteins. These two proteins were shown to be ZIPK by immunoblotting and protein sequencing. However, other researchers have detected the full-length 54 kDa protein in VSM tissues (Niiro and Ikebe, 2001; Endo et al., 2004; Vetterkind and Morgan, 2009) . The presence of a LZ motif in the full-length ZIPK sequence, and in certain MYPT1 isoforms, could provide an effective mechanism for linking the two proteins. However, the presence of the LZ does not enhance ZIPK activity toward MYPT1 (Niiro and Ikebe, 2001) . Furthermore, the presence of a LZ does not appear to be necessary for the localization of ZIPK to MLCP as demonstrated by the original isolation of the truncated 32 kDa kinase with MLCP activity in MacDonald et al. (2001a) and the coimmunoprecipitation of the 32 kDa isoform of ZIPK from bladder smooth muscle with MYPT1 in MacDonald et al. (2001a) , and by subsequent studies showing that both fulllength ZIPK and ZIPK lacking the LZ can interact with MYPT1 (Endo et al., 2004; Takamoto et al., 2006) . However, the LZ does appear to have some role in controlling both the activity and the cellular localization of ZIPK. Mutation of the LZ resulted in a decreased ability of ZIPK to induce cell death when over-expressed in NIH3T3 cells (Kawai et al., 1998) and in a predominantly nuclear localization of the kinase (Graves et al., 2005) . Additional investigations are required to explore how ZIPK signaling is compartmentalized within VSM to independently regulate LC 20 and MYPT1/CPI-17 phosphorylation.
Previous evidence has suggested that ZIPK could be activated in VSM in response to agonist stimulation (MacDonald et al., 2001a) ; however, the upstream signaling architecture for the regulation of ZIPK activity in VSM (e.g., GPCRs and activating kinase pathways) has not been interrogated in detail. Herein, we provide the first examination of GPCR-mediated modulation of ZIPK contractile responses. The inhibition of ZIPK by HS38 significantly influenced the VSM contractile responses to a variety of physiologic agonists, acting via their cognate receptors, including phenylephrine, U46619, AngII, and ET-1. Canonical /calmodulin (CaM)-dependent MLCK, which phosphorylates the 20-kDa regulatory light chains of myosin II at Ser19. Agonist stimulation of GPCRs also results in the activation of ROCK via G 12/13 , a Rho-guanine nucleotide exchange factor (RhoGEF) and the small GTPase RhoA. Activated ROCK leads to inhibition of MLCP activity, increased LC 20 phosphorylation, and smooth muscle contraction. VSM contraction can be evoked independently of Ca 2+ by direct phosphorylation of MYPT1 at Thr697 and Thr855, or indirectly via phosphorylation of CPI-17 at Thr38. Two discrete pools of ZIPK play distinct roles in Ca 2+ sensitization of VSM contraction: 1) a pool of constitutively active ZIPK (indicated in green), whose activity is unmasked by inhibition of MLCP activity, for example, by CLa and phosphorylates LC 20 at Thr18 and Ser19, and 2) a pool of ZIPK (indicated in blue) is activated by phosphorylation by ROCK, leading to phosphorylation of MYPT1 and CPI-17 and decreased MLCP activity. Other kinases, including integrin-linked kinase (ILK), can also phosphorylate LC 20 at Thr18 and Ser19, as well as CPI-17 at Thr38 and MYPT1 at Thr697 and Thr855.
